Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I).
By use of a mouse mucosal immunization model, LT-IIb(T13I), a nontoxic mutant type II heat-labile enterotoxin, was shown to have potent mucosal and systemic adjuvant properties. In contrast to LT-IIb, which binds strongly to ganglioside receptors decorated with either N-acetylneuraminic acid (NeuAc) or N-glycolylneuraminic acid (NeuGc), LT-IIb(T13I) binds NeuAc gangliosides much less well. Rather, LT-IIb(T13I) binds preferentially to NeuGc gangliosides. To determine if the adjuvant properties of LT-IIb(T13I) are altered in the absence of NeuGc ganglioside receptors, experiments were conducted using a Cmah-null mouse line which is deficient in the synthesis of NeuGc gangliosides. Several immunomodulatory properties of LT-IIb(T13I) were shown to be dependent on NeuGc gangliosides. LT-IIb(T13I) had reduced binding activity for NeuGc-deficient B cells and macrophages; binding to NeuGc-deficient T cells and dendritic cells (DC) was essentially undetectable. Treatment of Cmah-null macrophages with LT-IIb(T13I), however, upregulated the transcription of interleukin-4 (IL-4), IL-6, IL-17, and gamma interferon (IFN-gamma), four cytokines important for promoting immune responses. The production of mucosal IgA and serum IgG against an immunizing antigen was augmented in NeuGc-deficient mice administered LT-IIb(T13I) as a mucosal adjuvant. Notably, NeuGc gangliosides are not expressed in humans. Still, treatment of human monocytes with LT-IIb(T13I) induced the secretion of IL-6, an inflammatory cytokine that mediates differential control of leukocyte activation. These results suggested that NeuAc gangliosides are sufficient to mediate the immunomodulatory properties of LT-IIb(T13I) in mice and in human cells. The nontoxic mutant enterotoxin LT-IIb(T13I), therefore, is potentially a new and safe human mucosal adjuvant.
Nawar
Hesham F
HF
Witebsky Center for Microbial Pathogenesis and Immunology and Department of Microbiology and Immunology, University at Buffalo, State University of New York at Buffalo, Buffalo, New York 14214, USA.
Berenson
Charles S
CS
Hajishengallis
George
G
Takematsu
Hiromu
H
Mandell
Lorrie
L
Clare
Ragina L
RL
Connell
Terry D
TD
D000276:Adjuvants, Immunologic; D000818:Animals; D001402:B-Lymphocytes / Q000737:chemistry / Q000276:immunology; D001427:Bacterial Toxins / Q000276:immunology* / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism; D004768:Enterotoxins / Q000276:immunology* / Q000378:metabolism*; D029968:Escherichia coli Proteins / Q000276:immunology* / Q000378:metabolism*; D005732:Gangliosides / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D018928:Immunity, Mucosal; D007114:Immunization; D007155:Immunologic Factors / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000737:chemistry / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009000:Monocytes / Q000737:chemistry / Q000276:immunology; D019158:N-Acetylneuraminic Acid / Q000737:chemistry*; D011956:Receptors, Cell Surface / Q000378:metabolism
D000276:Adjuvants, Immunologic; D001427:Bacterial Toxins; D016207:Cytokines; D004768:Enterotoxins; D029968:Escherichia coli Proteins; D005732:Gangliosides; D007155:Immunologic Factors; D011956:Receptors, Cell Surface; C034993:ganglioside receptor; C027538:heat-labile enterotoxin, E coli; D019158:N-Acetylneuraminic Acid
Infect Immun. 2007 Mar;75(3):1413-23
17220318
Infect Immun. 1986 Nov;54(2):587-9
3533784
Infect Immun. 2004 Nov;72(11):6351-8
15501764
Am J Physiol. 1992 Jun;262(6 Pt 1):C1341-55
1616002
Eur J Immunol. 1998 Apr;28(4):1243-50
9565364
Mol Microbiol. 1995 Apr;16(1):21-31
7651134
Biochemistry. 1996 May 21;35(20):6375-84
8639583
Infect Immun. 1980 May;28(2):486-93
6995311
Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):583-95
8224473
Infect Immun. 1988 Jul;56(7):1748-53
3290106
Infect Immun. 1997 May;65(5):1695-700
9125549
Infect Immun. 1986 Nov;54(2):529-36
2429930
Mol Cell Biol. 2007 Apr;27(8):3008-22
17296732
Biochemistry. 1994 Nov 1;33(43):12886-95
7947695
Science. 1996 Jan 19;271(5247):348-50
8553069
Biochim Biophys Acta. 1957 Jun;24(3):604-11
13436486
J Infect Dis. 2005 Nov 1;192(9):1628-33
16206078
APMIS. 1995 Mar;103(3):161-79
7538771
Med Microbiol Immunol. 1998 Jun;187(1):3-10
9749977
J Immunol. 2006 Jun 15;176(12):7645-56
16751412
J Immunol. 2007 Apr 15;178(8):4811-9
17404262
Neurochem Res. 2002 Aug;27(7-8):637-47
12374199
J Immunol. 2000 Nov 1;165(9):4778-82
11045998
J Biol Chem. 2000 Mar 24;275(12):8633-40
10722703
Expert Rev Vaccines. 2007 Oct;6(5):821-34
17931161
Vaccine. 2005 Mar 7;23(15):1804-13
15734046
Immunol Today. 1999 Feb;20(2):95-101
10098329
Infect Immun. 2007 Feb;75(2):621-33
17118982
Infect Immun. 2000 Jan;68(1):281-7
10603399
J Leukoc Biol. 1989 Mar;45(3):221-30
2494280
J Immunol. 2005 Sep 15;175(6):3463-8
16148087
Infect Immun. 2005 Oct;73(10):6892-902
16177369
Infect Immun. 1997 Dec;65(12):4943-50
9393780
J Biol Chem. 2007 Mar 9;282(10):7532-42
17227759
Glycobiology. 1997 Dec;7(8):1215-27
9455923
Infect Immun. 2001 Jul;69(7):4486-92
11401990
Proc Natl Acad Sci U S A. 1977 Oct;74(10):4396-400
200916
Proc Natl Acad Sci U S A. 1977 Aug;74(8):3307-11
198781
Infect Immun. 2005 Mar;73(3):1330-42
15731030
J Dent Res. 2005 Dec;84(12):1104-16
16304439
Rev Med Virol. 2003 Sep-Oct;13(5):293-310
12931340
Immunol Today. 1999 Nov;20(11):493-500
10529776
Glycobiology. 2010 Jan;20(1):41-54
19749203
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11751-6
9751737
Nat Immunol. 2005 Nov;6(11):1069-70
16239919
Infect Immun. 2005 May;73(5):2718-27
15845474
Curr Mol Med. 2005 Sep;5(6):591-7
16178769
PLoS One. 2009;4(4):e5190
19360100